Filing Details

Accession Number:
0001415889-24-023093
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-09 21:20:10
Reporting Period:
2024-09-05
Accepted Time:
2024-09-09 21:20:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1438533 Travere Therapeutics Inc. TVTX Pharmaceutical Preparations (2834) 262383102
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1902368 Jula Inrig C/O Travere Therapeutics, Inc.
3611 Valley Centre Drive, Suite 300
San Diego CA 92130
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-05 6,750 $0.00 64,824 No 4 A Direct
Common Stock Disposition 2024-09-09 2,191 $11.52 62,633 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.
  2. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.